Saturday 17 October 2026
Export AIM’s income statement to Excel — free account
AIM ImmunoTech Inc.
AIM ImmunoTech Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88,000.00, down 48.2% from fiscal 2024. In the quarter to June 2026, revenue grew 4.00%, EPS grew 94.0% and free cash flow fell 167.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.17
0.00
0.00%
Follow AIM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
50.46 | 27.31 | 20.23 | 49.71 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.04) | (0.94) | (0.90) | (1.10) | |
P/B ratio |
0.62 | 1.21 | 0.00 | 0.00 | |
Price to Tangible BV |
0.79 | 5.54 | 0.00 | 0.00 | |
EV/Sales |
(49.75) | (30.51) | (1.20) | 31.53 | |
EV/EBITDA |
0.49 | 0.33 | 0.01 | 0.00 | |
EV/Operating CF |
0.33 | 0.25 | 0.01 | (0.27) | |
EV/FCF |
0.32 | 0.25 | 0.01 | (0.26) | |
Quick Ratio |
2.01 | 0.96 | 0.49 | 0.60 | |
Current Ratio |
2.11 | 1.01 | 0.53 | 0.64 | |
Net Debt/EBITDA |
3.17 | 2.83 | 0.98 | 1.04 | |
Debt/Assets |
0.00% | 2.45% | 16.03% | 0.00% | |
Debt/Equity |
0.00 | 0.10 | (0.09) | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF/Net income |
1.21 | 0.90 | 0.48 | 1.55 | |
Capex/Depreciation |
(0.30) | (0.15) | (0.12) | 0.00 | |
Interest Coverage |
(11.91) | (7.32) | (7.55) | (16.53) | |
Research and Development Expense of Revenue |
2,265.38% | 2,190.91% | 5,061.90% | 2,334.62% | |
Selling, General and Administrative Expense of Revenue |
11,326.92% | 8,009.09% | 8,904.76% | 6,915.38% | |
Intangible Assets out of Total Assets |
0.13 | 0.19 | 0.29 | 0.37 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
1.14 | (0.10) | (6.89) | (1.62) | |
Graham Number |
0.00 | 0.00 | 38.13 | 36.37 | |
Earnings Yield |
(1,043.32%) | (1,081.36%) | (971.82%) | (761.28%) | |
Free Cash Flow Yield |
(305.05%) | (454.91%) | (636.97%) | (239.50%) | |
Revenue per Share |
0.00 | 0.01 | 0.01 | 0.01 | |
Operating CF per Share |
(0.27) | (0.62) | (1.23) | (2.43) | |
Capex per Share |
(0.01) | (0.01) | (0.06) | 0.00 | |
Free Cash Flow per Share |
(0.27) | (0.63) | (1.29) | (2.43) | |
Cash per Share |
0.58 | 1.35 | 1.88 | 1.15 | |
Shareholders Equity per Share |
0.45 | 0.49 | (6.04) | (2.90) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.45 | 0.49 | (6.04) | (2.90) | |
Free Cash Flow |
(4.70) | (2.75) | (2.08) | (5.08) | |
Working Capital |
5.49 | 0.07 | (2.93) | (1.47) | |
Capital Expenditures |
(0.11) | (0.03) | (0.09) | 0.00 | |
Net Current Asset Value |
5.45 | (0.25) | (12.27) | (9.00) | |
EV/EBIT |
0.42 | 0.28 | 0.01 | 0.00 | |
Capex to Sales |
4.31 | 1.59 | 4.52 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | 0.02 | — | |
Average Payables |
3.89 | 4.08 | 4.01 | 3.76 | |
Average Assets |
8.43 | 7.42 | 7.20 | 9.54 | |
Average Common Equity |
0.60 | (0.87) | (5.55) | (1.58) |
Columns are period end dates